In the United States, the mortality burden of respiratory syncytial virus (RSV) infection in children younger than 1 year exceeds that of all influenza strains combined,
1 and RSV infection is the leading cause of pediatric hospitalizations, resulting in more than 90 000 hospitalizations annually.
2 Globally, RSV is estimated to cause an annual 33.8 million severe acute lower respiratory tract infections in children younger than 5 years.
3,4 No vaccine protects against RSV, but palivizumab, a humanized monoclonal antibody marketed as Synagis (Medimmune), has been found to reduce hospitalizations by 55% (and as much as 72%) when delivered prophylactically to children at high risk.
5-7 Palivizumab prophylaxis has been approved in 83 countries
8 and is a primary control strategy for RSV infection worldwide.
9 Dosing policies and target groups are similar among developed countries and are based on international clinical trials.
5,10 Immunoprophylaxis is recommended for infants born at a gestational age of younger than 29 weeks and infants at risk for RSV-related hospitalization due to hemodynamically significant congenital heart disease, chronic lung disease of prematurity, congenital abnormalities, or lung conditions that compromise the handling of respiratory secretions.
11 In the United States, palivizumab is administered by monthly intramuscular injection during the RSV season for a total of up to 5 doses per patient.
10 Palivizumab administration is controversial because of its high cost,
2,12,13 which exceeded $10 665 for a 5-dose regimen in 2013
13 and can reach $15 000 for some patients.
14 The total annual cost of palivizumab worldwide is estimated to be $1.2 billion,
8,15 which is primarily borne by insurance companies and national payers. Although the manufacturer provides some rebates, palivizumab has been the most costly pharmaceutical item in some fiscal quarters of the Medicaid program.
16 Consequently, considerable interest exists in improving the effectiveness and reducing the costs of RSV prevention.
6,12,17